METRYL 500 Tablet

In patients with a history of hypersensitivity to Metronidazole or other Nitroimidazole derivatives.

Pain, tenderness, redness, or swelling over vein in which the medicine is given. Other side-effects are unsteadiness, fever or chills, sore throat, headache, numbness, tingling pain or weakness in the hands or feet, pain, seizures, skin itching, unusual tiredness or weakness, vaginal irritation or discharge.

Patients should be advised not to take alcohol during metronidazole therapy and for at least 48 hours afterwards because of the possibility of a disulfiram-like reaction.

Potentiation of anticoagulant therapy has been reported when metronidazole has been used with warfarin type oral anticoagulants.

Lithium retention accompanied by evidence of possible renal damage has been reported in patients treated simultaneously with lithium and metronidazole. Lithium treatment should be tapered or withdrawn before administering metronidazole.

Metronidazole reduces the clearance of 5-fluorouracil and can therefore result in increased toxicity of 5-fluorouracil.

Studies have not been done in humans.

Metronidazole has not been shown to cause birth defects in animal studies; however, use is not recommended during the first trimester of pregnancy.

Use is not recommended in nursing mothers since metronidazole passes into the breast milk.

Metronidazole should be given with caution in the following conditions-

anaemia or other blood disorders, liver disease, disease of the nervous system, seizures etc.

The 5-nitro group of metronidazole undergoes reductive transformation to an active metabolite that exerts a lethal effect on DNA of bacteria and ultimately contributes to cell death.